Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Novel Biomarker Predicts Response to Therapy in Patients with a Rare Form of Metastatic Colorectal Cancer

By LabMedica International staff writers
Posted on 29 Sep 2022

Cancer researchers have identified a biomarker that predicts response of patients with microsatellite stable BRAF V600E metastatic colorectal cancer (MSS mCRC) to treatment with combined anti-BRAF/EGFR therapy. More...

Microsatellites are repeated sequences of DNA. These sequences can be made of units of one to six base pairs in length that are repeated and reside adjacent to each other in the genome. Although the length of microsatellites can vary from person to person and contributes to the individual DNA "fingerprint", each individual has microsatellites of a set length.

Mutations in BRAFV600E occur in around 10% of mCRC, and while relatively rare, they associate with a poor prognosis. Since a large fraction of mCRC patients do not respond to the recently approved combined anti-BRAF/EGFR therapy, there is an urgent need to identify the molecular determinants of treatment response.

In this regard, investigators at Vall d'Hebron Institute of Oncology (Barcelona, Spain) used whole-exome sequencing and targeted next generation sequencing (NGS) to analyze a discovery cohort of patients with mCRC(BRAF-V600E) treated with anti-BRAF/EGFR therapy. In addition, a control cohort of patients with mCRC(BRAF-V600E) receiving standard chemotherapies and anti-angiogenic agents (and not exposed to anti-BRAF) was evaluated. Data obtained from the molecular analyses were integrated with clinical correlates of response and survival.

Results revealed that inactivating mutations in RNF43, a negative regulator of the WNT signaling pathway, predicted improved response rates and survival outcomes in patients with microsatellite-stable (MSS) tumors. The response rate among patients with a BRAFV600E MSS mCRC carrying a RNF43 mutation reached 72.7%, and only 30.8% in those without the mutation. In patients with tumors harboring the RNF43 mutation, median disease-free progression was 10.1 months versus 4.1 months and overall survival in the former was 13.6 months compared to seven months in the latter.

The investigators concluded that patients with MSS-mCRC(BRAF-V600E) tumors harboring loss-of-function mutations in RNF43 responded favorably to combined anti-BRAF/EGFR therapy, whereas those with functional RNF43 derived limited benefit from this treatment.

"We performed extensive genomic analysis of over 20,000 genes. In total, we analyzed data from 166 patients which represents a significant number considering the rarity of this tumor subtype that accounts for around 10% of all colorectal cancers," said senior author Dr. Rodrigo A. Toledo, a translational investigator at Vall d'Hebron Institute of Oncology. "Our data point to RNF43 as a potential stratification biomarker that could help steer treatment decision making as well as define the optimal sequence of treatment in patients with microsatellite stable, BRAF V600E- mutant metastatic colorectal cancer. As importantly, it could also help to identify those patients for whom alternative treatment options are very much needed."

The study was published in the September 12, 2022, online edition of the journal Nature Medicine.

Related Links:
Vall d'Hebron Institute of Oncology 


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Portable Electronic Pipette
Mini 96
8-Channel Pipette
SAPPHIRE 20–300 µL
New
Gold Member
Hybrid Pipette
SWITCH
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.